Share

cover art for AstraZeneca to invest $2.5 billion in China research and development hub

Daily SumUp

AstraZeneca to invest $2.5 billion in China research and development hub

Season 1, Ep. 7118

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China-based research – plus the company’s first vaccine-manufacturing facility in the country.


The British-Swedish drug maker, which saw one of its executives detained in China last year, announced a multibillion-dollar investment deal last week, before its CEO attended a global business forum in Beijing.

AstraZeneca inked a US$2.5 billion contract with the city government of Beijing to establish the firm’s sixth global strategic R&D centre, with high-end industrialisation projects conducted in the Chinese capital to advance life sciences throughout the country.

More episodes

View all episodes